Receptor News and Research

RSS

GPR21 inhibitors may hold promise for diabetes

In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues. Obesity is a major factor that contributes to insulin resistance, which can eventually lead to type 2 diabetes. Previous studies have shown that proinflammatory molecules found in fat tissue decreases sensitivity of tissues to insulin.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

Glucocorticoid steroids in intelligent medicine specifically hits relevant cells

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids.

1 Jun 2012

Formation of blood vessels in tumors attacked from two angles

As soon as they have grown to pinhead size, tumors rely on the formation of new blood vessels - a process which is scientifically called angiogenesis. Interfering with this process (antiangiogenesis) is considered to be a promising approach in cancer medicine. However, those drugs that are already available for preventing the sprouting of new blood capillaries have failed to fulfill the high expectations placed on them.

1 Jun 2012

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Researchers discover binding partner of TDF hormone

Researchers at Clarkson University in Potsdam, N.Y., led by Chemistry & Biomolecular Science Professor Costel C. Darie, in collaboration with researchers from Columbia University, have now found the binding partner of TDF, a pituitary hormone that had previously been shown to reduce cancer progression in breast cancer cells, in prostate cancer as well.

1 Jun 2012

Personalized medicine and the Human Genome Project

It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.

1 Jun 2012

LILRB2 receptor plays an important role in keeping stem cells from differentiating

An immune-system receptor plays an unexpected but crucially important role in keeping stem cells from differentiating and in helping blood cancer cells grow, researchers at UT Southwestern Medical Center report today in the journal Nature.

1 Jun 2012

Scientists succeed in solving first structure of a Wnt protein

The 20 proteins in the Wnt family are some of the most important proteins in controlling how an organism develops and grows, but for 30 years scientists have not known what these vital proteins actually look like. The proteins have eluded standard visualization techniques, in large part because they do not dissolve well in the water-based liquids normally used for biochemical studies.

1 Jun 2012

Ketamine reduces suicidal thoughts in patients with bipolar depression

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide is high. Antidepressants are commonly prescribed to treat or prevent the depressive episodes, but they are not universally effective. Many patients still continue to experience periods of depression even while being treated, and many patients must try several different types of antidepressants before finding one that works for them.

31 May 2012

Genetics can predict success of smoking cessation and need for medications

Genetics can help determine whether a person is likely to quit smoking on his or her own or need medication to improve the chances of success, according to research published in today's American Journal of Psychiatry. Researchers say the study moves health care providers a step closer to one day providing more individualized treatment plans to help patients quit smoking.

31 May 2012

Study reveals new evidence of trans-cranial bright light's effect to brain functions

A recent placebo-controlled study reveals new evidence of trans-cranial bright light's effect to brain functions when administered through the ear. Bright light stimulation was found to increase activity in brain areas related to processing of visual sensory information and tactile stimuli. The findings constitute the first ever published scientific article about functional modulation of the brain with bright light delivered to the brain through the ears. The study was published today May 29th, 2012 in the World Journal of Neuroscience.

30 May 2012

Positive results from RedHill’s RHB-103 bioequivalence trial on acute migraine

RedHill Biopharma Ltd., an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), patent protected, new formulations and combinations of existing drugs, announces positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine.

30 May 2012

Researchers discover new HIV-suppressing protein

Scientists have identified a new HIV-suppressing protein in the blood of people infected with the virus. In laboratory studies, the protein, called CXCL4 or PF-4, binds to HIV such that it cannot attach to or enter a human cell.

30 May 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

29 May 2012

New insight into immune-cell movement patterns

By pairing an intimate knowledge of immune-system function with a deep understanding of statistical physics, a cross-disciplinary team at the University of Pennsylvania has arrived at a surprising finding: T cells use a movement strategy to track down parasites that is similar to strategies that predators such as monkeys, sharks and blue-fin tuna use to hunt their prey.

28 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration.

25 May 2012

Thioridazine drug successfully kills human cancer stem cells

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.

25 May 2012